IN2014DN07384A - - Google Patents

Info

Publication number
IN2014DN07384A
IN2014DN07384A IN7384DEN2014A IN2014DN07384A IN 2014DN07384 A IN2014DN07384 A IN 2014DN07384A IN 7384DEN2014 A IN7384DEN2014 A IN 7384DEN2014A IN 2014DN07384 A IN2014DN07384 A IN 2014DN07384A
Authority
IN
India
Prior art keywords
compounds
disclosed
mediated
pyrimidinebased
pyrazolo
Prior art date
Application number
Other languages
English (en)
Inventor
Yingzhi Bi
Kenneth Gordon Carson
Giovanni Cianchetta
Michael Alan Green
Godwin Kumi
Alan Main
Yulian Zhang
Glenn Gregory Zipp
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of IN2014DN07384A publication Critical patent/IN2014DN07384A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN7384DEN2014 2012-03-09 2013-03-05 IN2014DN07384A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (1)

Publication Number Publication Date
IN2014DN07384A true IN2014DN07384A (pt) 2015-04-24

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7384DEN2014 IN2014DN07384A (pt) 2012-03-09 2013-03-05

Country Status (26)

Country Link
US (3) US8946415B2 (pt)
EP (1) EP2834243B1 (pt)
JP (1) JP6418950B2 (pt)
KR (1) KR101965025B1 (pt)
CN (1) CN104302649B (pt)
AR (1) AR090292A1 (pt)
AU (1) AU2013230128B2 (pt)
BR (1) BR112014022000A8 (pt)
CA (1) CA2866143C (pt)
DK (1) DK2834243T3 (pt)
ES (1) ES2676224T3 (pt)
HK (1) HK1201257A1 (pt)
HU (1) HUE038786T2 (pt)
IL (1) IL234486A (pt)
IN (1) IN2014DN07384A (pt)
MX (1) MX345830B (pt)
NZ (1) NZ630721A (pt)
PL (1) PL2834243T3 (pt)
PT (1) PT2834243T (pt)
RU (1) RU2014140735A (pt)
SG (1) SG11201405561RA (pt)
TR (1) TR201808280T4 (pt)
TW (1) TW201341386A (pt)
UY (1) UY34668A (pt)
WO (1) WO2013134228A1 (pt)
ZA (1) ZA201406149B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2834243B1 (en) 2012-03-09 2018-04-25 Lexicon Pharmaceuticals, Inc. PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
MX347917B (es) 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
JP2016509066A (ja) 2013-02-22 2016-03-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アダプター関連キナーゼ1(aak1)の阻害剤としての5h−クロメノ[3,4−c]ピリジン
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2735729T3 (es) 2014-01-24 2019-12-20 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteínas cinasas
CN106132951B (zh) * 2014-01-31 2019-02-12 百时美施贵宝公司 基于喹啉的激酶抑制剂
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
US20170239249A1 (en) * 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
CA2971024C (en) * 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
US10174044B2 (en) 2015-04-10 2019-01-08 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018000297A2 (pt) 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
BR112018001065A2 (pt) 2015-07-21 2018-09-11 Tp Therapeutics, Inc. macrociclos diarila quirais e usos dos mesmos
MY194700A (en) * 2015-11-02 2022-12-15 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
MX2019001125A (es) 2016-07-28 2019-06-12 Tp Therapeutics Inc Inhibidores de cinasa macrociclica.
AU2017353315B2 (en) 2016-11-02 2021-09-16 Janssen Pharmaceutica Nv (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
CN109923116B (zh) * 2016-11-02 2022-12-06 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物
MX2019005123A (es) 2016-11-02 2019-06-20 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
CN117946114A (zh) 2017-07-28 2024-04-30 武田药品工业株式会社 Tyk2抑制剂与其用途
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
JP7150356B2 (ja) * 2017-12-22 2022-10-11 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾロ[1,5-a]ピリミジン化合物並びにその医薬組成物および使用
WO2019144885A1 (zh) 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
WO2020063751A1 (en) * 2018-09-27 2020-04-02 Fochon Pharmaceuticals, Ltd. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
EP3866789A4 (en) * 2018-10-15 2022-07-06 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
EP4138829A1 (en) 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. Aak1 inhibitors for use in treating viral infections
US11666575B2 (en) 2020-04-21 2023-06-06 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
KR101634833B1 (ko) * 2008-10-22 2016-06-29 어레이 바이오파마 인크. TRK 키나아제 억제제로서 치환된 피라졸로[1,5­a] 피리미딘 화합물
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TW201113286A (en) 2009-09-03 2011-04-16 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
WO2011087999A1 (en) * 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
US9416132B2 (en) * 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
MX347917B (es) 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
DK2822555T3 (en) * 2012-03-09 2018-02-05 Lexicon Pharmaceuticals Inc Inhibition of adapter-associated kinase 1 for the treatment of pain
EP2834243B1 (en) 2012-03-09 2018-04-25 Lexicon Pharmaceuticals, Inc. PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
TW201341386A (zh) 2013-10-16
HUE038786T2 (hu) 2018-11-28
MX345830B (es) 2017-02-17
JP6418950B2 (ja) 2018-11-07
DK2834243T3 (en) 2018-07-23
AU2013230128A1 (en) 2014-09-25
EP2834243B1 (en) 2018-04-25
AR090292A1 (es) 2014-11-05
CA2866143A1 (en) 2013-09-12
SG11201405561RA (en) 2014-10-30
CN104302649A (zh) 2015-01-21
BR112014022000A8 (pt) 2021-06-15
PL2834243T3 (pl) 2018-09-28
KR101965025B1 (ko) 2019-04-02
US20150183792A1 (en) 2015-07-02
EP2834243A1 (en) 2015-02-11
AU2013230128B2 (en) 2017-08-17
ES2676224T3 (es) 2018-07-17
RU2014140735A (ru) 2016-04-27
WO2013134228A1 (en) 2013-09-12
MX2014010589A (es) 2014-09-18
KR20140138864A (ko) 2014-12-04
US8946415B2 (en) 2015-02-03
IL234486A (en) 2016-10-31
CN104302649B (zh) 2017-06-23
HK1201257A1 (en) 2015-08-28
BR112014022000A2 (pt) 2017-06-20
TR201808280T4 (tr) 2018-07-23
US9403832B2 (en) 2016-08-02
PT2834243T (pt) 2018-08-01
JP2015509535A (ja) 2015-03-30
UY34668A (es) 2013-10-31
US20170129896A1 (en) 2017-05-11
US20130253194A1 (en) 2013-09-26
CA2866143C (en) 2020-08-04
ZA201406149B (en) 2016-06-29
NZ630721A (en) 2016-12-23

Similar Documents

Publication Publication Date Title
IN2014DN07384A (pt)
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
NZ626937A (en) Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
PH12015500988B1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
RS61319B1 (sr) Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za lečenje kancera
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
MX2016003457A (es) Compuestos aminopirimidina sustituidos y metodos de uso.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
WO2013163190A8 (en) Dna-pk inhibitors
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
UA107952C2 (uk) ПОХІДНІ ІМІДАЗО[1,2-a]ПІРАЗИНУ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ НЕВРОЛОГІЧНИХ, ПСИХІАТРИЧНИХ І МЕТАБОЛІЧНИХ РОЗЛАДІВ І ЗАХВОРЮВАНЬ
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MD20150023A2 (ro) Piridinone biciclice noi
NZ624063A (en) Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
NZ629499A (en) Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
NZ630170A (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX340574B (es) Imidazo pirazinas.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази